Back to Journals » ImmunoTargets and Therapy
ImmunoTargets and Therapy
Editor-in-Chief: Professor Michael R Shurin
ImmunoTargets and Therapy is an international journal that aims to present and publish basic and clinical research on the aspects of immunology in health and disease. ImmunoTargets and Therapy is primarily focused on the immunological basis of disease and explores the evidence behind new and existing immunotherapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
This journal offers Accelerated Publication.
Articles:
- View all (339)
- Volume 15, 2026 (37)
- Volume 14, 2025 (90)
- Volume 13, 2024 (56)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Latest articles:
- 5 records -
Role of Cytokines in Bone Diseases and Their Therapeutic Application
Guha A, Wahi P, Lal G
ImmunoTargets and Therapy 2026, 15:604392
Published Date: 7 May 2026
Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors
Fountzilas E, Kurzrock R, Nishizaki D, Szabo A, Pabla S, DePietro P, Jensen TJ, Kato S, Tsimberidou AM
ImmunoTargets and Therapy 2026, 15:578703
Published Date: 4 May 2026
Tumor-Promoting Crosstalk of MMP11⁺ Fibroblasts and SPP1⁺ Macrophages Drive Poor Prognosis in Breast Cancer: Integrated Multi-Omics Analysis
Huang R, Zhan Z, Huang S, Cao W, Li J, Mao M
ImmunoTargets and Therapy 2026, 15:564498
Published Date: 29 April 2026
RNA Sequencing Analyses and Validation of Immune-Related Genes in EBV-Specific Cytotoxic T Lymphocytes During Latent Infection
Guan Z, Ao X, Zhou L, Yu C, Zhang Z, Li D
ImmunoTargets and Therapy 2026, 15:568661
Published Date: 27 April 2026
Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort
Mitura-Lesiuk M, Najda P, Rdzanek O, Bogucka J, Różycka K, Dubaj M, Zawitkowska J
ImmunoTargets and Therapy 2026, 15:603087
Published Date: 23 April 2026
